Lazertinib Mesylate Drug Asset Due Diligence Report 2026

This Lazertinib Mesylate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Lazertinib Mesylate can convert its Small molecule drug profile and EGFR L858R x EGFR T790M x EGFR-Ex19del biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Lazertinib Mesylate (query alias: Lazertinib Mesylate)
Modality / target	Small molecule drug; EGFR L858R x EGFR T790M x EGFR-Ex19del; EGFR T790M inhibitors, EGFR exon 19 deletion inhibitors, EGFR exon 21 L858R mutation inhibitors
Highest global status	Approved
Originator	Janssen Biotech, Inc.
Active developers	Janssen Research & Development LLC, Yuhan Corp., Janssen-Cilag International NV

The MCP disease footprint includes EGFR-mutated non-small Cell Lung Cancer, Non-Small Cell Lung Cancer, EGFR exon 19 Deletions Mutant Non-small Cell Lung Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
JPRN-jRCTs071250140	Phase 2	募集中	100	プロトコール治療開始後12カ月時点までのVTE発生割合
NCT07507188	Phase 2	Not yet recruiting	80	• scRNA-seq and/or spatial RNA sequencing analysis. Multiplex IHC and/or FACS analysis.
JPRN-jRCTs031250560	Phase 2	募集中	70	Progression-Free Survival (by blinded independent central review; BICR)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Overall survival of first-line amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Updated results from the CHRYSALIS-2 study.

Phase 1; n=49; evaluation: Positive. Reported fields: mOS = 41.0 Month ( 27.7 - NE)

Randomized phase II study of amivantamab + lazertinib versus afatinib in patients with uncommon/compound EGFR-mutated non-small cell lung cancer (WJOG17323L: AGEHA study).

Phase 2; n=70; evaluation: Positive. Reported fields: AE(Discontinuation) = 5.0 % ; AE(Discontinuation) = 10.0 %

COPERNICUS, a pragmatic phase 2b study of first-line (1L) subcutaneous (SC) amivantamab (ami) + lazertinib (laz) with supportive care in EGFR-mutated advanced NSCLC: Early safety results.

Phase 2; n=190; evaluation: Positive. Reported fields: AE(dermatologic) = 26.0 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Lazertinib Mesylate addresses EGFR-mutated non-small Cell Lung Cancer, Non-Small Cell Lung Cancer, EGFR exon 19 Deletions Mutant Non-small Cell Lung Cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-10-31	Yuhan promotes Leclaza+Rybrevant first-line lung cancer therapy with Janssen Korea	Approved	Financial terms not disclosed
2018-11-05	Janssen Biotech partners with Yuhan to globally develop and commercialize Lazertinib for NSCLC, excluding Republic of Korea.	Phase 2	US$50.0M upfront; US$900.0M milestones
2016-07-28	Yuhan And Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. Enter Into Exclusive License And Co-Development Agreement For 3rd -Generation EGFR-Targeted Therapy In China	Preclinical	US$120.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO